ImpediMed Launches L-Dex System in U.S.

January 8, 2016

ImpediMed has initiated the U.S. launch of its L-Dex system to aid in the clinical assessment of lymphedema.

L-Dex features a bioimpedance spectroscopy, a noninvasive system for measuring tissue composition and fluid status. This helps identify lymphedema up to 10 months before there is evidence of limb swelling, the Carlsbad, Calif.-based company says.

Roughly 3 million to 5 million people live with lymphedema in the U.S. due to trauma resulting from impaired lymphatic systems. — Michael Cipriano